Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome

FEBS Journal

Volumn 278, Issue 23, 2011, Pages 4649-4667

  Brosnahan, Amanda J ^a   Schlievert, Patrick M ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

MRSA; mucosal immunity; Staphylococcus aureus; Streptococcus pyogenes; superantigen; toxic shock syndrome

Indexed keywords

BACTERIAL ANTIGEN; CYTOLYSIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAPHYLOCOCCUS ANTIGEN; STREPTOCOCCUS ANTIGEN; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN STRUCTURE; BINDING SITE; BIOCHEMISTRY; CELL INTERACTION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EPITHELIUM CELL; GRAM POSITIVE BACTERIUM; HUMAN; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MUCOSAL IMMUNITY; NONHUMAN; OUTSIDE IN SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TOXIC SHOCK SYNDROME;

ANIMALS; ANTIGEN-PRESENTING CELLS; EPITHELIAL CELLS; GRAM-POSITIVE BACTERIA; HUMANS; PROTEIN CONFORMATION; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; SUPERANTIGENS; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

EID: 80054860481     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08151.x     Document Type: Review

References (164)

1. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298, 1763-1771. (Pubitemid 47598444)
2. Lowy FD, (1998) Staphylococcus aureus infections. N Engl J Med 339, 520-532.
3. Schlievert PM, Strandberg KL, Lin YC, Peterson ML, &, Leung DY, (2010) Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J Allergy Clin Immunol 125, 39-49.
4. Schlievert PM, &, Bohach GA, (2007) Staphylococcal and streptococcal superantigens: an update. In Superantigens: Molecular Basis for Their Role in Human Diseases (, Kotb MA, &, Fraser JD, eds), pp. 21-36. ASM Press, Washington, DC.
5. Patti JM, Allen BL, McGavin MJ, &, Hook M, (1994) MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 48, 585-617.
6. Bohach GA, Fast DJ, Nelson RD, &, Schlievert PM, (1990) Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17, 251-272. (Pubitemid 20249880)
7. Dinges MM, Orwin PM, &, Schlievert PM, (2000) Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13, 16-34. (Pubitemid 30039341)
8. Lina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin-Marche E, &, Mariuzza R, (2004) Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 189, 2334-2336. (Pubitemid 38757208)
9. McCormick JK, Yarwood JM, &, Schlievert PM, (2001) Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 55, 77-104. (Pubitemid 32978101)
10. Assimacopoulos AP, Stoehr JA, &, Schlievert PM, (1997) Mitogenic factors from group G streptococci associated with scarlet fever and streptococcal toxic shock syndrome. Adv Exp Med Biol 418, 109-114. (Pubitemid 27438389)
11. Shimomura Y, Okumura K, Murayama SY, Yagi J, Ubukata K, Kirikae T, &, Miyoshi-Akiyama T, (2011) Complete genome sequencing and analysis of a Lancefield group G Streptococcus dysgalactiae subsp. equisimilis strain causing streptococcal toxic shock syndrome (STSS). BMC Genomics 12, 17.
12. Wagner JG, Schlievert PM, Assimacopoulos AP, Stoehr JA, Carson PJ, &, Komadina K, (1996) Acute group G streptococcal myositis associated with streptococcal toxic shock syndrome: case report and review. Clin Infect Dis 23, 1159-1161. (Pubitemid 26367506)
13. Paillot R, Darby AC, Robinson C, Wright NL, Steward KF, Anderson E, Webb K, Holden MT, Efstratiou A, Broughton K, et al. (2010) Identification of three novel superantigen-encoding genes in Streptococcus equi subsp. zooepidemicus, szeF, szeN, and szeP. Infect Immun 78, 4817-4827.
14. Zell C, Resch M, Rosenstein R, Albrecht T, Hertel C, &, Gotz F, (2008) Characterization of toxin production of coagulase-negative staphylococci isolated from food and starter cultures. Int J Food Microbiol 127, 246-251.
15. Hovde CJ, Marr JC, Hoffmann ML, Hackett SP, Chi YI, Crum KK, Stevens DL, Stauffacher CV, &, Bohach GA, (1994) Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1. Mol Microbiol 13, 897-909. (Pubitemid 24272209)
16. Schlievert PM, Jablonski LM, Roggiani M, Sadler I, Callantine S, Mitchell DT, Ohlendorf DH, &, Bohach GA, (2000) Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals. Infect Immun 68, 3630-3634. (Pubitemid 30340467)
17. Baker M, Gutman DM, Papageorgiou AC, Collins CM, &, Acharya KR, (2001) Structural features of a zinc binding site in the superantigen strepococcal pyrogenic exotoxin A (SpeA1): implications for MHC class II recognition. Protein Sci 10, 1268-1273. (Pubitemid 32476489)
18. Earhart CA, Vath GM, Roggiani M, Schlievert PM, &, Ohlendorf DH, (2000) Structure of streptococcal pyrogenic exotoxin A reveals a novel metal cluster. Protein Sci 9, 1847-1851.
19. Papageorgiou AC, Collins CM, Gutman DM, Kline JB, O'Brien SM, Tranter HS, &, Acharya KR, (1999) Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors. EMBO J 18, 9-21. (Pubitemid 29005018)
20. Petersson K, Pettersson H, Skartved NJ, Walse B, &, Forsberg G, (2003) Staphylococcal enterotoxin H induces V alpha-specific expansion of T cells. J Immunol 170, 4148-4154. (Pubitemid 36428179)
21. Saline M, Rodstrom KE, Fischer G, Orekhov VY, Karlsson BG, &, Lindkvist-Petersson K, (2010) The structure of superantigen complexed with TCR and MHC reveals novel insights into superantigenic T cell activation. Nat Commun 1, 119.
22. Pumphrey N, Vuidepot A, Jakobsen B, Forsberg G, Walse B, &, Lindkvist-Petersson K, (2007) Cutting edge: evidence of direct TCR alpha-chain interaction with superantigen. J Immunol 179, 2700-2704.
23. Brouillard JN, Gunther S, Varma AK, Gryski I, Herfst CA, Rahman AK, Leung DY, Schlievert PM, Madrenas J, Sundberg EJ, et al. (2007) Crystal structure of the streptococcal superantigen SpeI and functional role of a novel loop domain in T cell activation by group V superantigens. J Mol Biol 367, 925-934. (Pubitemid 46386067)
24. Gunther S, Varma AK, Moza B, Kasper KJ, Wyatt AW, Zhu P, Rahman AK, Li Y, Mariuzza RA, McCormick JK, et al. (2007) A novel loop domain in superantigens extends their T cell receptor recognition site. J Mol Biol 371, 210-221. (Pubitemid 47030464)
25. Bergdoll MS, &, Schlievert PM, (1984) Toxic-shock syndrome toxin. Lancet ii, 691.
26. Davis JP, Chesney PJ, Wand PJ, &, LaVenture M, (1980) Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 303, 1429-1435.
27. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, et al. (1980) Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 303, 1436-1442.
28. Todd JK, Kapral FA, Fishaut M, &, Welch TR, (1978) Toxic shock syndrome associated with phage group 1 staphylococci. Lancet 2, 1116-1118. (Pubitemid 9060056)
29. Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, &, Broome CV, (1982) Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med 96, 871-874. (Pubitemid 12088886)
30. Parsonnet J, (1998) Case definition of staphylococcal TSS: a proposed revision incorporating laboratory findings. Int Congr Symp Ser 229, 15. (Pubitemid 128747008)
31. Hill DR, Brunner ME, Schmitz DC, Davis CC, Flood JA, Schlievert PM, Wang-Weigand SZ, &, Osborn TW, (2005) In vivo assessment of human vaginal oxygen and carbon dioxide levels during and post menses. J Appl Physiol 99, 1582-1591. (Pubitemid 43014370)
32. Schlievert PM, &, Blomster DA, (1983) Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. J Infect Dis 147, 236-242. (Pubitemid 13195102)
33. Yarwood JM, &, Schlievert PM, (2000) Oxygen and carbon dioxide regulation of toxic shock syndrome toxin 1 production by Staphylococcus aureus MN8. J Clin Microbiol 38, 1797-1803. (Pubitemid 30253918)
34. Schlievert PM, Tripp TJ, &, Peterson ML, (2004) Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 42, 2875-2876. (Pubitemid 38747565)
35. Jarraud S, Cozon G, Vandenesch F, Bes M, Etienne J, &, Lina G, (1999) Involvement of enterotoxins G and I in staphylococcal toxic shock syndrome and staphylococcal scarlet fever. J Clin Microbiol 37, 2446-2449. (Pubitemid 29337259)
36. MacDonald KL, Osterholm MT, Hedberg CW, Schrock CG, Peterson GF, Jentzen JM, Leonard SA, &, Schlievert PM, (1987) Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA 257, 1053-1058. (Pubitemid 17031493)
37. Kim HJ, Kim DH, &, Ko DH, (2010) Coagulase-positive staphylococcal necrotizing fasciitis subsequent to shoulder sprain in a healthy woman. Clin Orthop Surg 2, 256-259.
38. Lalich IJ, &, Sam-Agudu NA, (2010) Community-acquired methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a healthy adolescent male. Minn Med 93, 44-46.
39. Kravitz GR, Dries DJ, Peterson ML, &, Schlievert PM, (2005) Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 40, 941-947. (Pubitemid 40418298)
40. Assimacopoulos A, &, Schlievert PM, (2008) Staphylococcal and streptococcal toxic shock and Kawasaki syndromes. In Clinical Infectious Disease (, Schlossberg D, Ed.), pp. 129-134. Cambridge University Press, New York, NY.
41. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, &, Daum RS, (1998) Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279, 593-598. (Pubitemid 28110205)
42. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, Kreiswirth BN, &, Schlievert PM, (2003) Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47, 196-203. (Pubitemid 36070364)
43. Assimacopoulos AP, Strandberg KL, Rotschafer JH, &, Schlievert PM, (2009) Extreme pyrexia and rapid death due to Staphylococcus aureus infection: analysis of 2 cases. Clin Infect Dis 48, 612-614.
44. Kotler DP, Sandkovsky U, Schlievert PM, &, Sordillo EM, (2007) Toxic shock-like syndrome associated with staphylococcal enterocolitis in an HIV-infected man. Clin Infect Dis 44, e121-e123.
45. Skov L, Olsen JV, Giorno R, Schlievert PM, Baadsgaard O, &, Leung DY, (2000) Application of staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T cells by a superantigen-mediated mechanism. J Allergy Clin Immunol 105, 820-826. (Pubitemid 30226459)
46. John CC, Niermann M, Sharon B, Peterson ML, Kranz DM, &, Schlievert PM, (2009) Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin Infect Dis 49, 1893-1896.
47. Birkhaug KE, (1925) Studies in scarlet fever II. Studies on the use of convalescent scarlet fever serum and Dochez' scarlatinal antistreptococcic serum for the treatment of scarlet fever. Bull Johns Hopkins Hosp 36, 134-171.
48. Cone LA, Woodard DR, Schlievert PM, &, Tomory GS, (1987) Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 317, 146-149. (Pubitemid 17092152)
49. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, &, Kaplan E, (1989) Severe group A streptococcal infections associated with a toxic shock- like syndrome and scarlet fever toxin A. N Engl J Med 321, 1-7. (Pubitemid 19170377)
50. Schlievert PM, Bettin KM, &, Watson DW, (1979) Reinterpretation of the Dick test: role of group A streptococcal pyrogenic exotoxin. Infect Immun 26, 467-472.
51. Schlievert PM, Case LC, Strandberg KL, Tripp TJ, Lin YC, &, Peterson ML, (2007) Vaginal Staphylococcus aureus superantigen profile shift from 1980 and 1981 to 2003, 2004, and 2005. J Clin Microbiol 45, 2704-2707. (Pubitemid 47295510)
52. Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim MH, Hauser AR, &, Schlievert PM, (1992) Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 339, 518-521.
53. Schlievert PM, Assimacopoulos AP, &, Cleary PP, (1996) Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J Lab Clin Med 127, 13-22.
54. Hauser AR, Stevens DL, Kaplan EL, &, Schlievert PM, (1991) Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 29, 1562-1567.
55. Lee PK, &, Schlievert PM, (1989) Quantification and toxicity of group A streptococcal pyrogenic exotoxins in an animal model of toxic shock syndrome-like illness. J Clin Microbiol 27, 1890-1892. (Pubitemid 19182902)
56. Goshorn SC, &, Schlievert PM, (1989) Bacteriophage association of streptococcal pyrogenic exotoxin type C. J Bacteriol 171, 3068-3073. (Pubitemid 19145654)
57. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A, Green K, Peeples J, Wade J, Thomson G, et al. (2002) An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 8, 1398-1404. (Pubitemid 36019425)
58. Osterholm MT, Davis JP, Gibson RW, Mandel JS, Wintermeyer LA, Helms CM, Forfang JC, Rondeau J, &, Vergeront JM, (1982) Tri-state toxic-state syndrome study. I. Epidemiologic findings. J Infect Dis 145, 431-440. (Pubitemid 12158327)
59. Schlievert PM, &, Kelly JA, (1984) Clindamycin-induced suppression of toxic-shock syndrome-associated exotoxin production. J Infect Dis 149, 471. (Pubitemid 14138254)
60. Cone LA, Stone RA, Schlievert PM, Sneider RA, Rubin AM, Jesser K, &, Renker SW, (2006) An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C. Scand J Infect Dis 38, 960-963. (Pubitemid 44869264)
61. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, &, Low DE, (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28, 800-807. (Pubitemid 29169419)
62. Leung DY, Walsh P, Giorno R, &, Norris DA, (1993) A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 100, 225-228. (Pubitemid 23083160)
63. Schlievert PM, Bettin KM, &, Watson DW, (1979) Production of pyrogenic exotoxin by groups of streptococci: association with group A. J Infect Dis 140, 676-681. (Pubitemid 10214190)
64. Smoot LM, McCormick JK, Smoot JC, Hoe NP, Strickland I, Cole RL, Barbian KD, Earhart CA, Ohlendorf DH, Veasy LG, et al. (2002) Characterization of two novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of Streptococcus pyogenes associated with multiple disease outbreaks. Infect Immun 70, 7095-7104. (Pubitemid 35387947)
65. Kim SW, Grant JE, Kim SI, Swanson TA, Bernstein GA, Jaszcz WB, Williams KA, &, Schlievert PM, (2004) A possible association of recurrent streptococcal infections and acute onset of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 16, 252-260. (Pubitemid 39244551)
66. Strandberg KL, Peterson ML, Schaefers MM, Case LC, Pack MC, Chase DJ, &, Schlievert PM, (2009) Reduction in Staphylococcus aureus growth and exotoxin production and in vaginal interleukin 8 levels due to glycerol monolaurate in tampons. Clin Infect Dis 49, 1711-1717.
67. Schlievert PM, Osterholm MT, Kelly JA, &, Nishimura RD, (1982) Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome. Ann Intern Med 96, 937-940. (Pubitemid 12088904)
68. Eschenbach DA, Thwin SS, Patton DL, Hooton TM, Stapleton AE, Agnew K, Winter C, Meier A, &, Stamm WE, (2000) Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin Infect Dis 30, 901-907. (Pubitemid 32250327)
69. Patton DL, Thwin SS, Meier A, Hooton TM, Stapleton AE, &, Eschenbach DA, (2000) Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol 183, 967-973.
70. van der Bijl P, Thompson IO, &, Squier CA, (1997) Comparative permeability of human vaginal and buccal mucosa to water. Eur J Oral Sci 105, 571-575. (Pubitemid 127760549)
71. Wertz PW, &, van den Bergh B, (1998) The physical, chemical and functional properties of lipids in the skin and other biological barriers. Chem Phys Lipids 91, 85-96. (Pubitemid 28142956)
72. Thompson IO, van der Bijl P, van Wyk CW, &, van Eyk AD, (2001) A comparative light-microscopic, electron-microscopic and chemical study of human vaginal and buccal epithelium. Arch Oral Biol 46, 1091-1098. (Pubitemid 33086338)
73. Brosnahan AJ, Mantz MJ, Squier CA, Peterson ML, &, Schlievert PM, (2009) Cytolysins augment superantigen penetration of stratified mucosa. J Immunol 182, 2364-2373.
74. Peterson ML, Ault K, Kremer MJ, Klingelhutz AJ, Davis CC, Squier CA, &, Schlievert PM, (2005) The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1. Infect Immun 73, 2164-2174. (Pubitemid 40470816)
75. Brosnahan AJ, Schaefers MM, Amundson WH, Mantz MJ, Squier CA, Peterson ML, &, Schlievert PM, (2008) Novel toxic shock syndrome toxin-1 amino acids required for biological activity. Biochemistry 47, 12995-13003.
76. Lancefield RC, &, Hare R, (1935) The serological differentiation of pathogenic and non-pathogenic strains of hemolytic streptococci from parturient women. J Exp Med 61, 335-349.
77. Bray S, &, Morgan J, (2006) Two cases of group A streptococcal vulvovaginitis in premenopausal adults in a sexual health setting. Sex Health 3, 187-188. (Pubitemid 44325579)
78. Hansen MT, Sanchez VT, Eyster K, &, Hansen KA, (2007) Streptococcus pyogenes pharyngeal colonization resulting in recurrent, prepubertal vulvovaginitis. J Pediatr Adolesc Gynecol 20, 315-317. (Pubitemid 47375133)
79. Hedlund P, (1953) Acute vulvovaginitis in streptococcal infections. Nord Med 49, 566-568.
80. Heller RH, Joseph JM, &, Davis HJ, (1969) Vulvovaginitis in the premenarcheal child. J Pediatr 74, 370-377.
81. Meltzer MC, &, Schwebke JR, (2008) Lactational amenorrhea as a risk factor for group a streptococcal vaginitis. Clin Infect Dis 46, e112-e115. (Pubitemid 351706757)
82. O'Connor PA, &, Oliver WJ, (1985) Group A beta-hemolytic streptococcal vulvovaginitis: a recurring problem. Pediatr Emerg Care 1, 94-95. (Pubitemid 16141145)
83. Schwartz RH, Wientzen RL, &, Barsanti RG, (1982) Vulvovaginitis in prepubertal girls: the importance of group A Streptococcus. South Med J 75, 446-447. (Pubitemid 12010400)
84. Sobel JD, Funaro D, &, Kaplan EL, (2007) Recurrent group A streptococcal vulvovaginitis in adult women: family epidemiology. Clin Infect Dis 44, e43-e45.
85. Kushnaryov VM, Bergdoll MS, MacDonald HS, Vellinga J, &, Reiser R, (1984) Study of staphylococcal toxic shock syndrome toxin in human epithelial cell culture. J Infect Dis 150, 535-545. (Pubitemid 14013974)
86. Kushnaryov VM, MacDonald HS, Reiser R, &, Bergdoll MS, (1984) Staphylococcal toxic shock toxin specifically binds to cultured human epithelial cells and is rapidly internalized. Infect Immun 45, 566-571. (Pubitemid 14066166)
87. Aubert V, Schneeberger D, Sauty A, Winter J, Sperisen P, Aubert JD, &, Spertini F, (2000) Induction of tumor necrosis factor alpha and interleukin-8 gene expression in bronchial epithelial cells by toxic shock syndrome toxin 1. Infect Immun 68, 120-124. (Pubitemid 30016686)
88. Yu RL, &, Dong Z, (2009) Proinflammatory impact of Staphylococcus aureus enterotoxin B on human nasal epithelial cells and inhibition by dexamethasone. Am J Rhinol Allergy 23, 15-20.
89. Damm M, Quante G, Rosenbohm J, &, Rieckmann R, (2006) Proinflammatory effects of Staphylococcus aureus exotoxin B on nasal epithelial cells. Otolaryngol Head Neck Surg 134, 245-249. (Pubitemid 43187124)
90. O'Brien GJ, Riddell G, Elborn JS, Ennis M, &, Skibinski G, (2006) Staphylococcus aureus enterotoxins induce IL-8 secretion by human nasal epithelial cells. Respir Res 7, 115.
91. Thakur A, Clegg A, Chauhan A, &, Willcox MD, (1997) Modulation of cytokine production from an EpiOcular corneal cell culture model in response to Staphylococcus aureus superantigen. Aust N Z J Ophthalmol 25 (Suppl 1), S43-S45. (Pubitemid 27337280)
92. Herz U, Ruckert R, Wollenhaupt K, Tschernig T, Neuhaus-Steinmetz U, Pabst R, &, Renz H, (1999) Airway exposure to bacterial superantigen (SEB) induces lymphocyte-dependent airway inflammation associated with increased airway responsiveness - a model for non-allergic asthma. Eur J Immunol 29, 1021-1031. (Pubitemid 29119083)
93. Rajagopalan G, Iijima K, Singh M, Kita H, Patel R, &, David CS, (2006) Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class II transgenic mice. Infect Immun 74, 1284-1296. (Pubitemid 43185568)
94. Rajagopalan G, Sen MM, Singh M, Murali NS, Nath KA, Iijima K, Kita H, Leontovich AA, Gopinathan U, Patel R, et al. (2006) Intranasal exposure to staphylococcal enterotoxin B elicits an acute systemic inflammatory response. Shock 25, 647-656. (Pubitemid 44297027)
95. Krakauer T, Pitt L, &, Hunt RE, (1997) Detection of interleukin-6 and interleukin-2 in serum of rhesus monkeys exposed to a nonlethal dose of staphylococcal enterotoxin B. Mil Med 162, 612-615. (Pubitemid 27494608)
96. Strandberg KL, Rotschafer JH, Vetter SM, Buonpane RA, Kranz DM, &, Schlievert PM, (2010) Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis 202, 1690-1697.
97. Rajagopalan G, Smart MK, Patel R, &, David CS, (2006) Acute systemic immune activation following conjunctival exposure to staphylococcal enterotoxin B. Infect Immun 74, 6016-6019. (Pubitemid 44484590)
98. Schlievert PM, (1982) Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect Immun 36, 123-128. (Pubitemid 12156414)
99. Kim YB, &, Watson DW, (1970) A purified group A streptococcal pyrogenic exotoxin. Physiochemical and biological properties including the enhancement of susceptibility to endotoxin lethal shock. J Exp Med 131, 611-622.
100. Rajagopalan G, Smart MK, Murali N, Patel R, &, David CS, (2007) Acute systemic immune activation following vaginal exposure to staphylococcal enterotoxin B-implications for menstrual shock. J Reprod Immunol 73, 51-59. (Pubitemid 46161831)
101. Spiekermann GM, &, Nagler-Anderson C, (1998) Oral administration of the bacterial superantigen staphylococcal enterotoxin B induces activation and cytokine production by T cells in murine gut-associated lymphoid tissue. J Immunol 161, 5825-5831. (Pubitemid 28535947)
102. Wang B, Schlievert PM, Gaber AO, &, Kotb M, (1993) Localization of an immunologically functional region of the streptococcal superantigen pepsin-extracted fragment of type 5 M protein. J Immunol 151, 1419-1429. (Pubitemid 23219279)
103. Hoffmann ML, Jablonski LM, Crum KK, Hackett SP, Chi YI, Stauffacher CV, Stevens DL, &, Bohach GA, (1994) Predictions of T-cell receptor- and major histocompatibility complex-binding sites on staphylococcal enterotoxin C1. Infect Immun 62, 3396-3407. (Pubitemid 24232126)
104. Jett M, Neill R, Welch C, Boyle T, Bernton E, Hoover D, Lowell G, Hunt RE, Chatterjee S, &, Gemski P, (1994) Identification of staphylococcal enterotoxin B sequences important for induction of lymphocyte proliferation by using synthetic peptide fragments of the toxin. Infect Immun 62, 3408-3415. (Pubitemid 24232127)
105. Arad G, Levy R, Hillman D, &, Kaempfer R, (2000) Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 6, 414-421. (Pubitemid 30208158)
106. Kaempfer R, Arad G, Levy R, &, Hillman D, (2002) Defense against biologic warfare with superantigen toxins. Isr Med Assoc J 4, 520-523. (Pubitemid 34752241)
107. Arad G, Hillman D, Levy R, &, Kaempfer R, (2004) Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide. Immunol Lett 91, 141-145. (Pubitemid 38296371)
108. Arad G, Hillman D, Levy R, &, Kaempfer R, (2001) Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock. J Leukoc Biol 69, 921-927. (Pubitemid 32577893)
109. Rajagopalan G, Sen MM, &, David CS, (2004) In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infect Immun 72, 6733-6737. (Pubitemid 39425463)
110. Shupp JW, Jett M, &, Pontzer CH, (2002) Identification of a transcytosis epitope on staphylococcal enterotoxins. Infect Immun 70, 2178-2186. (Pubitemid 34242221)
111. Hamad AR, Marrack P, &, Kappler JW, (1997) Transcytosis of staphylococcal superantigen toxins. J Exp Med 185, 1447-1454. (Pubitemid 27187601)
112. Mitchell DT, Levitt DG, Schlievert PM, &, Ohlendorf DH, (2000) Structural evidence for the evolution of pyrogenic toxin superantigens. J Mol Evol 51, 520-531. (Pubitemid 32001971)
113. Choi Y, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, Marrack P, &, Kotzin BL, (1990) Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 172, 981-984. (Pubitemid 20301247)
114. Schlievert PM, Bettin KM, &, Watson DW, (1978) Effect of antipyretics on group A streptococcal pyrogenic exotoxin fever production and ability to enhance lethal endotoxin shock. Proc Soc Exp Biol Med 157, 472-475. (Pubitemid 8328248)
115. Dinges MM, Jessurun J, &, Schlievert PM, (1998) Comparisons of mouse and rabbit models of toxic shock syndrome. Int Congr Symp Ser 229, 167-168.
116. Dinges MM, &, Schlievert PM, (2001) Comparative analysis of lipopolysaccharide-induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. Infect Immun 69, 7169-7172. (Pubitemid 32995481)
117. Schlievert PM, &, Watson DW, (1979) Biogenic amine involvement in pyrogenicity and enhancement of lethal endotoxin shock by group A streptococcal pyrogenic exotoxin. Proc Soc Exp Biol Med 162, 269-274. (Pubitemid 10200489)
118. Kotzin BL, Leung DY, Kappler J, &, Marrack P, (1993) Superantigens and their potential role in human disease. Adv Immunol 54, 99-166. (Pubitemid 23289252)
119. Norrby-Teglund A, Thulin P, Gan BS, Kotb M, McGeer A, Andersson J, &, Low DE, (2001) Evidence for superantigen involvement in severe group a streptococcal tissue infections. J Infect Dis 184, 853-860. (Pubitemid 32881089)
120. Kotb M, Norrby-Teglund A, McGeer A, Green K, &, Low DE, (2003) Association of human leukocyte antigen with outcomes of infectious diseases: the streptococcal experience. Scand J Infect Dis 35, 665-669. (Pubitemid 37336890)
121. Norrby-Teglund A, Nepom GT, &, Kotb M, (2002) Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles. Eur J Immunol 32, 2570-2577.
122. Nooh MM, El-Gengehi N, Kansal R, David CS, &, Kotb M, (2007) HLA transgenic mice provide evidence for a direct and dominant role of HLA class II variation in modulating the severity of streptococcal sepsis. J Immunol 178, 3076-3083. (Pubitemid 46333188)
123. Nooh MM, Nookala S, Kansal R, &, Kotb M, (2011) Individual genetic variations directly effect polarization of cytokine responses to superantigens associated with streptococcal sepsis: implications for customized patient care. J Immunol 186, 3156-3163.
124. Kozono H, Parker D, White J, Marrack P, &, Kappler J, (1995) Multiple binding sites for bacterial superantigens on soluble class II MHC molecules. Immunity 3, 187-196.
125. Li H, Llera A, Malchiodi EL, &, Mariuzza RA, (1999) The structural basis of T cell activation by superantigens. Annu Rev Immunol 17, 435-466. (Pubitemid 29241131)
126. Kim J, Urban RG, Strominger JL, &, Wiley DC, (1994) Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 266, 1870-1874.
127. Moza B, Varma AK, Buonpane RA, Zhu P, Herfst CA, Nicholson MJ, Wilbuer AK, Seth NP, Wucherpfennig KW, McCormick JK, et al. (2007) Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1. EMBO J 26, 1187-1197.
128. Wen R, Cole GA, Surman S, Blackman MA, &, Woodland DL, (1996) Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T cells. J Exp Med 183, 1083-1092. (Pubitemid 26113972)
129. 2+-mediated homodimerization. EMBO J 15, 6832-6840.
130. Li Y, Li H, Dimasi N, McCormick JK, Martin R, Schuck P, Schlievert PM, &, Mariuzza RA, (2001) Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 14, 93-104. (Pubitemid 32144690)
131. Schad EM, Papageorgiou AC, Svensson LA, &, Acharya KR, (1997) A structural and functional comparison of staphylococcal enterotoxins A and C2 reveals remarkable similarity and dissimilarity. J Mol Biol 269, 270-280. (Pubitemid 27248290)
132. Sundstrom M, Hallen D, Svensson A, Schad E, Dohlsten M, &, Abrahmsen L, (1996) The co-crystal structure of staphylococcal enterotoxin type A with Zn2+ at 2.7 A resolution. Implications for major histocompatibility complex class II binding. J Biol Chem 271, 32212-32216. (Pubitemid 26422256)
133. Abrahmsen L, Dohlsten M, Segren S, Bjork P, Jonsson E, &, Kalland T, (1995) Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J 14, 2978-2986.
134. Hudson KR, Tiedemann RE, Urban RG, Lowe SC, Strominger JL, &, Fraser JD, (1995) Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J Exp Med 182, 711-720.
135. Li PL, Tiedemann RE, Moffat SL, &, Fraser JD, (1997) The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action. J Exp Med 186, 375-383. (Pubitemid 27332895)
136. Tripp TJ, McCormick JK, Webb JM, &, Schlievert PM, (2003) The zinc-dependent major histocompatibility complex class II binding site of streptococcal pyrogenic exotoxin C is critical for maximal superantigen function and toxic activity. Infect Immun 71, 1548-1550. (Pubitemid 36254343)
137. Roussel A, Anderson BF, Baker HM, Fraser JD, &, Baker EN, (1997) Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules. Nat Struct Biol 4, 635-643. (Pubitemid 27323446)
138. Proft T, Moffatt SL, Berkahn CJ, &, Fraser JD, (1999) Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 189, 89-102.
139. McCormick JK, Peterson ML, &, Schlievert PM, (2006) Toxins and superantigens of group A streptococci. In Gram Positive Pathogens (, Fishchetti VA, Novick RP, Ferretti JJ, Portnoy DA, &, Rood JI, eds), pp. 47-58. ASM Press, Washington, DC.
140. Marrack P, &, Kappler J, (1990) The staphylococcal enterotoxins and their relatives. Science 248, 1066.
141. Li H, Llera A, Tsuchiya D, Leder L, Ysern X, Schlievert PM, Karjalainen K, &, Mariuzza RA, (1998) Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity 9, 807-816. (Pubitemid 29024460)
142. Malchiodi EL, Eisenstein E, Fields BA, Ohlendorf DH, Schlievert PM, Karjalainen K, &, Mariuzza RA, (1995) Superantigen binding to a T cell
143. Sundberg EJ, Li H, Llera AS, McCormick JK, Tormo J, Schlievert PM, Karjalainen K, &, Mariuzza RA, (2002) Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. Structure 10, 687-699. (Pubitemid 34520468)
144. McCormick JK, Tripp TJ, Llera AS, Sundberg EJ, Dinges MM, Mariuzza RA, &, Schlievert PM, (2003) Functional analysis of the TCR binding domain of toxic shock syndrome toxin-1 predicts further diversity in MHC class II/superantigen/TCR ternary complexes. J Immunol 171, 1385-1392. (Pubitemid 36900071)
145. Bueno C, Lemke CD, Criado G, Baroja ML, Ferguson SS, Rahman AK, Tsoukas CD, McCormick JK, &, Madrenas J, (2006) Bacterial superantigens bypass Lck-dependent T cell receptor signaling by activating a Galpha11-dependent, PLC-beta-mediated pathway. Immunity 25, 67-78. (Pubitemid 44066827)
146. Taylor AL, &, Llewelyn MJ, (2010) Superantigen-induced proliferation of human CD4+CD25- T cells is followed by a switch to a functional regulatory phenotype. J Immunol 185, 6591-6598.
147. Rosene KA, Copass MK, Kastner LS, Nolan CM, &, Eschenbach DA, (1982) Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 96, 865-870. (Pubitemid 12088885)
148. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458, 1034-1038.
149. Altemeier WA, Lewis SA, Schlievert PM, Bergdoll MS, Bjornson HS, Staneck JL, &, Crass BA, (1982) Staphylococcus aureus associated with toxic shock syndrome: phage typing and toxin capability testing. Ann Intern Med 96, 978-982. (Pubitemid 12088916)
150. Prasad GS, Radhakrishnan R, Mitchell DT, Earhart CA, Dinges MM, Cook WJ, Schlievert PM, &, Ohlendorf DH, (1997) Refined structures of three crystal forms of toxic shock syndrome toxin-1 and of a tetramutant with reduced activity. Protein Sci 6, 1220-1227. (Pubitemid 27260156)
151. Murray DL, Earhart CA, Mitchell DT, Ohlendorf DH, Novick RP, &, Schlievert PM, (1996) Localization of biologically important regions on toxic shock syndrome toxin 1. Infect Immun 64, 371-374.
152. Prasad GS, Earhart CA, Murray DL, Novick RP, Schlievert PM, &, Ohlendorf DH, (1993) Structure of toxic shock syndrome toxin 1. Biochemistry 32, 13761-13766. (Pubitemid 2023165)
153. Hurley JM, Shimonkevitz R, Hanagan A, Enney K, Boen E, Malmstrom S, Kotzin BL, &, Matsumura M, (1995) Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1. J Exp Med 181, 2229-2235.
154. Kum WW, Wood JA, &, Chow AW, (1996) A mutation at glycine residue 31 of toxic shock syndrome toxin-1 defines a functional site critical for major histocompatibility complex class II binding and superantigenic activity. J Infect Dis 174, 1261-1270. (Pubitemid 26393905)
155. Baker MD, Gendlina I, Collins CM, &, Acharya KR, (2004) Crystal structure of a dimeric form of streptococcal pyrogenic exotoxin A (SpeA1). Protein Sci 13, 2285-2290. (Pubitemid 39128851)
156. Kline JB, &, Collins CM, (1997) Analysis of the interaction between the bacterial superantigen streptococcal pyrogenic exotoxin A (SpeA) and the human T-cell receptor. Mol Microbiol 24, 191-202. (Pubitemid 27160849)
157. Kline JB, &, Collins CM, (1996) Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A. Infect Immun 64, 861-869. (Pubitemid 26065560)
158. Schad EM, Zaitseva I, Zaitsev VN, Dohlsten M, Kalland T, Schlievert PM, Ohlendorf DH, &, Svensson LA, (1995) Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J 14, 3292-3301.
159. Omoe K, Nunomura W, Kato H, Li ZJ, Igarashi O, Araake M, Sano K, Ono HK, Abe Y, Hu DL, et al. (2010) High affinity of interaction between superantigen and T cell receptor Vbeta molecules induces a high level and prolonged expansion of superantigen-reactive CD4+ T cells. J Biol Chem 285, 30427-30435.
160. Grossman D, Van M, Mollick JA, Highlander SK, &, Rich RR, (1991) Mutation of the disulfide loop in staphylococcal enterotoxin A. Consequences for T cell recognition. J Immunol 147, 3274-3281.
161. Rahman AK, Herfst CA, Moza B, Shames SR, Chau LA, Bueno C, Madrenas J, Sundberg EJ, &, McCormick JK, (2006) Molecular basis of TCR selectivity, cross-reactivity, and allelic discrimination by a bacterial superantigen: integrative functional and energetic mapping of the SpeC-Vbeta2.1 molecular interface. J Immunol 177, 8595-8603. (Pubitemid 44893822)
162. Fernandez MM, Guan R, Swaminathan CP, Malchiodi EL, &, Mariuzza RA, (2006) Crystal structure of staphylococcal enterotoxin I (SEI) in complex with a human major histocompatibility complex class II molecule. J Biol Chem 281, 25356-25364. (Pubitemid 44401923)
163. Hennecke J, &, Wiley DC, (2002) Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J Exp Med 195, 571-581. (Pubitemid 34461502)
164. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, Stauffacher C, Strominger JL, &, Wiley DC, (1994) Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368, 711-718. (Pubitemid 24153410)